Cell Signaling Technology

Rab4 Antibody

#2167 · western blot · $136,317

60

Evidence Score · Well-Established

Used by 96 independent labs across 103 papers. How we score this →

100

Citing papers

17.9k

Combined citations

Supplier page Find this product

Research areas

RNA Research and Splicing8 Genetics and Neurodevelopmental Disorders8 MicroRNA in disease regulation8 Neuroscience and Neuropharmacology Research7 Lung Cancer Treatments and Mutations6 Immune Cell Function and Interaction6 interferon and immune responses5 Immune cells in cancer5

Papers citing this product

1

Circadian control of brain glymphatic and lymphatic fluid flow

Nature Communications·2020·637 cit.·DOI

2

Dysregulation of mTOR Signaling in Fragile X Syndrome

Journal of Neuroscience·2010·563 cit.·DOI

3

Toll-like Receptor 4 Resides in the Golgi Apparatus and Colocalizes with Internalized Lipopolysaccharide in Intestinal Epithelial Cells

The Journal of Experimental Medicine·2002·410 cit.·DOI

4

Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19

Immunity·2020·406 cit.·DOI

5

Hypersensitivity to mGluR5 and ERK1/2 Leads to Excessive Protein Synthesis in the Hippocampus of a Mouse Model of Fragile X Syndrome

Journal of Neuroscience·2010·384 cit.·DOI

6

Endoplasmic Reticulum Stress Is Important for the Manifestations of α-Synucleinopathy<i>In Vivo</i>

Journal of Neuroscience·2012·377 cit.·DOI

7

Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer

Journal of Molecular Signaling·2010·374 cit.·DOI

8

Coordinated Regulation of Cell Cycle Transcripts by p53-Inducible microRNAs, miR-192 and miR-215

Cancer Research·2008·352 cit.·DOI

9

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

Blood·2009·345 cit.·DOI

10

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Clinical Cancer Research·2016·325 cit.·DOI

Similar products

Product	Vendor	Evidence	Price	Papers
Rab4 Antibodyrabbit	StressMarq Biosciences	60	—	—

Rate this reagent

Used this in your lab? Leave a quick rating. Reviews are anonymous and verified by academic email before they appear.